Large Cap Biotech Analyst Fye and Major & Specialty Pharmaceuticals Analyst Schott discuss the viewpoint on Pfizer’s acquisition of Seagen on an Analyst/Industry conference call to be held on March 14 at 1 pm. Webcast Link
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on PFE:
- JPMorgan biotech/pharma analysts to hold analyst/industry conference call
- Seagen price target raised to $229 from $155 at RBC Capital
- Seagen price target raised to $229 from $141 at SVB Securities
- Seagen price target raised to $229 from $210 at Oppenheimer
- Seagen price target raised to $228 from $145 at Barclays
